Pantherna Therapeutics raises €3.0M Bridge round
2 April 2020· Hennigsdorf, Germany· health, biotech, materials, b2b, deep_hardware
The follow-up financing will accelerate Pantherna's R&D activities and broaden them, specifically for the development of mRNA therapeutics to treat ARDS induced by coronavirus infections.
Investors
LeadDetlev Riesner
Also participating
European Investment Fund
About Pantherna Therapeutics
Stage
Series A
Headquarters
Hennigsdorf, Germany
Founded
2017
Team Size
6–20
Sectors
healthbiotechmaterialsb2bdeep_hardware